Ocular Therapeutix (OCUL) – Company Press Releases
-
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
-
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
-
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
-
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
-
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
-
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
-
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
-
Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
-
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
-
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
-
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
-
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, a
-
Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
-
Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
-
Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
-
Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
-
Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
-
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
-
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
-
Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update
-
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
-
AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery
-
Ocular Therapeutix™ To Report Third Quarter 2023 Financial Results
-
Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
-
AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Su
-
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
-
Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
-
Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update
-
Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results
-
Ocular Therapeutix™ Announces Appointment of New Board Member
-
Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD
-
Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy
-
Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeti
-
Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference
-
AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Cataract Surgery Patients
-
Ocular Therapeutix™ Provides First Quarter 2023 Financial Results and Corporate Update
-
Ocular Therapeutix™ to Present at the JMP Securities Life Sciences Conference
-
Ocular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
-
Ocular Therapeutix™ To Report First Quarter 2023 Financial Results
-
AffaMed Therapeutics Announces Approval to Initiate a Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surg
-
Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
-
Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update
-
Ocular Therapeutix™ to Present at Cowen’s 43rd Annual Healthcare Conference
-
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2022 Financial Results
-
Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD
-
Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones
-
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
-
Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update
-
Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results
-
Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD
Back to OCUL Stock Lookup
